Weiss Ratings Reiterates "Sell (D-)" Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Key Points

• Weiss Ratings has reiterated a "sell (D-)" rating for BioCryst Pharmaceuticals (NASDAQ:BCRX), signaling ongoing concerns about the stock's performance.
• The company's stock recently traded up 4.7%, reaching $7.28, although it has seen a one-year range between $6.01 and $11.31.
• BioCryst Pharmaceuticals reported a substantial increase in revenue, posting $163.35 million for the quarter, which is a 49.5% rise compared to the same period last year.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report)'s stock had its "sell (d-)" rating reiterated by analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

BCRX has been the topic of several other reports. Needham & Company LLC restated a "buy" rating and set a $17.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, August 4th. Wedbush raised their target price on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a research report on Monday, June 30th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Evercore ISI reaffirmed an "in-line" rating and set a $8.00 target price on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 1st. Finally, Bank of America raised their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Tuesday, July 1st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.30.

BioCryst Pharmaceuticals Trading Up 4.7%

BioCryst Pharmaceuticals stock traded up $0.33 during mid-day trading on Wednesday, hitting $7.28. The stock had a trading volume of 5,782,312 shares, compared to its average volume of 3,636,893. The firm has a market capitalization of $1.53 billion, a P/E ratio of -40.44, a P/E/G ratio of 1.41 and a beta of 1.05. The firm's 50 day moving average is $8.06 and its 200 day moving average is $8.69. BioCryst Pharmaceuticals has a one year low of $6.01 and a one year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million during the quarter, compared to analysts' expectations of $149.59 million. The firm's revenue for the quarter was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.06) EPS. As a group, equities research analysts forecast that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the company's stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the transaction, the director owned 65,352 shares in the company, valued at approximately $556,145.52. This represents a 51.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 5.10% of the company's stock.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Allianz Asset Management GmbH raised its holdings in BioCryst Pharmaceuticals by 9.6% in the 1st quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company's stock valued at $103,000 after acquiring an additional 1,200 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in BioCryst Pharmaceuticals by 7.7% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,992 shares of the biotechnology company's stock valued at $161,000 after acquiring an additional 1,288 shares during the last quarter. Royal Bank of Canada raised its holdings in BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company's stock valued at $476,000 after acquiring an additional 1,458 shares during the last quarter. Captrust Financial Advisors raised its holdings in BioCryst Pharmaceuticals by 7.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company's stock valued at $198,000 after acquiring an additional 1,527 shares during the last quarter. Finally, Main Management ETF Advisors LLC grew its stake in shares of BioCryst Pharmaceuticals by 1.7% in the 2nd quarter. Main Management ETF Advisors LLC now owns 112,128 shares of the biotechnology company's stock valued at $1,005,000 after buying an additional 1,824 shares during the period. Institutional investors and hedge funds own 85.88% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.